Price Chart

Profile

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
URL https://www.wuxibiologics.com
Investor Relations URL N/A
HQ State/Province N/A
Sector Health Care
Industry Life Sciences Tools & Services
Equity Style Large Cap/Blend
Next Earnings Release Mar. 26, 2025 (est.)
Last Earnings Release Aug. 21, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
URL https://www.wuxibiologics.com
Investor Relations URL N/A
HQ State/Province N/A
Sector Health Care
Industry Life Sciences Tools & Services
Equity Style Large Cap/Blend
Next Earnings Release Mar. 26, 2025 (est.)
Last Earnings Release Aug. 21, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A